Search research articles
Contact Us
Filters
Showing results (71-80 of 81) with videos related to
Page
of 9
Sort By:
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin
|
June 21, 2001
Cardiac metabolism and function in patients with multiple sclerosis: a combined 31P-MR-spectroscopy and MRI study
M Beer, J Sandstede, F Weilbach, et al.
Leukemia
|
August 13, 2014
Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center
R B Walter, M Othus, A K Burnett, et al.
Hematological Oncology
|
August 31, 2025
CAR T-Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real-World Experiences From a Single Center on the Use of Radiotherapy
J T Jutzi, J Wampfler, C Ionescu, et al.
Bone Marrow Transplantation
|
December 20, 2016
Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience
J Meissner, H Finel, S Dietrich, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 22, 2017
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation
S K Metzelder, T Schroeder, M Lübbert, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
November 24, 2019
Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
J R Passweg, M Labopin, M Christopeit, et al.
Leukemia
|
July 16, 2016
Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio
J Versluis, F E M In 't Hout, R Devillier, et al.
Leukemia
|
July 22, 2022
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome
J J W M Janssen, B Löwenberg, M Manz, et al.
Leukemia
|
November 28, 2014
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years
J J Cornelissen, J Versluis, J R Passweg, et al.
Leukemia
|
February 6, 2020
Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
G J Ossenkoppele, D A Breems, G Stuessi, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 81) with videos related to
Sort By:
Page
of 9
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin
|
June 21, 2001
Cardiac metabolism and function in patients with multiple sclerosis: a combined 31P-MR-spectroscopy and MRI study
M Beer, J Sandstede, F Weilbach, et al.
Leukemia
|
August 13, 2014
Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center
R B Walter, M Othus, A K Burnett, et al.
Hematological Oncology
|
August 31, 2025
CAR T-Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real-World Experiences From a Single Center on the Use of Radiotherapy
J T Jutzi, J Wampfler, C Ionescu, et al.
Bone Marrow Transplantation
|
December 20, 2016
Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience
J Meissner, H Finel, S Dietrich, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 22, 2017
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation
S K Metzelder, T Schroeder, M Lübbert, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
November 24, 2019
Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
J R Passweg, M Labopin, M Christopeit, et al.
Leukemia
|
July 16, 2016
Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio
J Versluis, F E M In 't Hout, R Devillier, et al.
Leukemia
|
July 22, 2022
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome
J J W M Janssen, B Löwenberg, M Manz, et al.
Leukemia
|
November 28, 2014
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years
J J Cornelissen, J Versluis, J R Passweg, et al.
Leukemia
|
February 6, 2020
Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
G J Ossenkoppele, D A Breems, G Stuessi, et al.
Page
of 9